Skip to main content
Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
302.11
-6.40 (-2.07%)
At close: Apr 28, 2026, 4:00 PM EDT
303.28
+1.17 (0.39%)
After-hours: Apr 28, 2026, 4:31 PM EDT

Alnylam Pharmaceuticals Revenue

In the year 2025, Alnylam Pharmaceuticals had annual revenue of $3.71B with 65.19% growth. Alnylam Pharmaceuticals had revenue of $1.10B in the quarter ending December 31, 2025, with 84.95% growth.

Revenue (ttm)
$3.71B
Revenue Growth
+65.19%
P/S Ratio
10.86
Revenue / Employee
$1,485,575
Employees
2,500
Market Cap
40.31B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20253.71B1.47B65.19%
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Regeneron Pharmaceuticals 14.34B
BeOne Medicines AG 5.34B
Incyte 5.14B
argenx SE 4.24B
BioNTech SE 3.37B
Royalty Pharma 2.38B
Moderna 1.94B
Insmed 606.42M
Revenue Rankings

ALNY News

More News